18Sep2017 After the Boom: How’s It Going for Big Pharma Vets At Startups? /Luke Timmerman/0/All, People, The Edge18 Sep 2017 Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.